Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.

Ganesh RaghuMark J HamblinA Whitney BrownJeffrey A GoldenLawrence A HoMarlies S WijsenbeekMartina VasakovaAlberto PesciDanielle E Antin-OzerkisKeith C MeyerMichael KreuterTracy BurgessNikhil KamathFrancis DonaldsonLuca Richeldi

Published in: Respiratory research (2022)

Long-term treatment (up to 128 weeks) with rhPTX-2 was well tolerated in patients with IPF, with no new safety signals emerging in the OLE. The limited efficacy data over 128 weeks may suggest a trend towards a treatment effect. Trial registration NCT02550873; EudraCT 2014-004782-24.

Keyphrases

idiopathic pulmonary fibrosis
recombinant human
interstitial lung disease
randomized controlled trial
study protocol
electronic health record
machine learning
gestational age
artificial intelligence
open label
double blind